Lists of people executed in the United States

KuCoin Releases Social Trading Features for a Simpler and Better Trading Experience

Friday, October 22, 2021 - 2:00am

These features are available in a special space called KuCoin S, where invited users can experience new functions prior to their official launch on the KuCoin App.

Key Points: 
  • These features are available in a special space called KuCoin S, where invited users can experience new functions prior to their official launch on the KuCoin App.
  • View the full release here: https://www.businesswire.com/news/home/20211021005419/en/
    KuCoin Releases Social Trading Features (Graphic: Business Wire)
    The first debut of the social trading feature is aligned with the long-term vision of KuCoin, which is bringing crypto to the masses.
  • The integration of social and trading features will make crypto trading easier at various levels and help KuCoin transform into the largest social trading platform within the crypto industry.
  • Currently, social trading features are only available to invited users, and KuCoin will gradually send out more invitation codes.

IgA Nephropathy - Global Epidemiology Forecast to 2030: Coverage of the USA, EU5 and Japan - ResearchAndMarkets.com

Wednesday, October 20, 2021 - 1:33pm

This 'IgA Nephropathy (IgAN) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of IgA nephropathy and historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This 'IgA Nephropathy (IgAN) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of IgA nephropathy and historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The disease epidemiology covered in the report provides historical and forecasted IgA nephropathy symptoms epidemiology segmented as the prevalence of IgA nephropathy, gender-specific cases of IgA nephropathy, and age-specific cases of IgA nephropathy.
  • The epidemiology segment also provides the IgA Nephropathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The IgA Nephropathy epidemiology report will allow the user to:
    Develop business strategies by understanding the trends shaping and driving the global IgA Nephropathy market.

Alibaba Group Kicks Off 2021 11.11 Global Shopping Festival

Wednesday, October 20, 2021 - 8:21am

Alibaba Group Holding Limited (NYSE: BABA; HKEX: 9988) today officially kicked off its 13th annual 11.11 Global Shopping Festival (11.11 or Festival) with an emphasis on sustainability and inclusiveness.

Key Points: 
  • Alibaba Group Holding Limited (NYSE: BABA; HKEX: 9988) today officially kicked off its 13th annual 11.11 Global Shopping Festival (11.11 or Festival) with an emphasis on sustainability and inclusiveness.
  • View the full release here: https://www.businesswire.com/news/home/20211020005394/en/
    Alibaba Group today kicked off its 2021 11.11 Global Shopping Festival.
  • The 11.11 Global Shopping Festival began in 2009 with participation from just 27 merchants as an event for merchants and consumers to raise awareness about the value of online shopping.
  • For the latest news and updates on the 2021 11.11 Global Shopping Festival, please visit: www.alizila.com
    Alibaba Groups mission is to make it easy to do business anywhere.

X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial

Tuesday, October 19, 2021 - 1:00pm

Ms. de Craeckers appointment expands the X4 Board of Directors to nine members.

Key Points: 
  • Ms. de Craeckers appointment expands the X4 Board of Directors to nine members.
  • Ms. de Craecker joins the X4 Board of Directors following a distinguished career building multi-functional teams, formulating global commercial strategies for orphan drug and gene therapy products, and successfully launching multiple products across the globe.
  • Prior to that, Ms. de Craecker served as Senior Vice President and General Manager EMEA at Raptor Pharmaceuticals Europe.
  • Ms. Park joined X4 in September 2021 as Vice President, U.S. Commercial, bringing nearly 20 years of experience in life science marketing and commercial planning, development, and execution.

Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021

Tuesday, October 19, 2021 - 12:58pm

The event will feature presentations from multiple key opinion leaders (KOLs) as well as Axcellas management team.

Key Points: 
  • The event will feature presentations from multiple key opinion leaders (KOLs) as well as Axcellas management team.
  • Additionally, the company announced today that it will now operate as Axcella Therapeutics.
  • Axcella uses its website, www.axcellatx.com , as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
  • Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions.

Global Squamous Non-Small Cell Lung Cancer Pipeline Report 2021-2031: Reviews, Developer Landscape and Competitive Insights - ResearchAndMarkets.com

Tuesday, October 19, 2021 - 9:37am

The "Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • The "Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031" report features an extensive study on the marketed, clinical and preclinical molecules available/being developed for the treatment of Squamous Non-Small Cell Lung Cancer.
  • One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Squamous Non-Small Cell Lung Cancer, over the next decade.
  • What are the key geographies where research on squamous non-small cell lung cancer is being conducted?

Global Dental Lasers Market to 2025 - Insights, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Monday, October 18, 2021 - 12:54pm

Additionally, an all-inclusive account of the currently available dental lasers is provided, which will have an impact on the future market of dental lasers.

Key Points: 
  • Additionally, an all-inclusive account of the currently available dental lasers is provided, which will have an impact on the future market of dental lasers.
  • A detailed review of dental lasers market; historical and forecasted market size is included in the report, covering devices outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the dental lasers market.
  • The report helps in developing business strategies by understanding trends shaping and driving the dental lasers market.

A healthcare market research reports platform that offers built in primary research, complimentary expert connects and much more

Friday, October 15, 2021 - 11:30am

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- GRG Health, a global leader in healthcare insights launches healthcare market insight reports platform Growth+ Market Reports powered with expert interviews and complimentary analysts' hours with each report.

Key Points: 
  • NEW YORK, Oct. 15, 2021 /PRNewswire/ -- GRG Health, a global leader in healthcare insights launches healthcare market insight reports platform Growth+ Market Reports powered with expert interviews and complimentary analysts' hours with each report.
  • GRG Health a global market leader in healthcare expert interviews with access to healthcare professionals across 50+ countries are addressing the unmet need of high quality primary research powered reports with Growth Plus Market Reports.
  • Growth + Market Reports, is a global life sciences market research reports platform that offers high quality market insights reports with a unique GrowthMIX approach.
  • All Growth+ reports come loaded with primary research, however the most differentiating factor remains complimentary access to Expert Connects Globally and Analyst Hours to build customizations complimentary with each report.

A healthcare market research reports platform that offers built in primary research, complimentary expert connects and much more

Friday, October 15, 2021 - 11:34am

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- GRG Health, a global leader in healthcare insights launches healthcare market insight reports platform Growth+ Market Reports powered with expert interviews and complimentary analysts' hours with each report.

Key Points: 
  • NEW YORK, Oct. 15, 2021 /PRNewswire/ -- GRG Health, a global leader in healthcare insights launches healthcare market insight reports platform Growth+ Market Reports powered with expert interviews and complimentary analysts' hours with each report.
  • GRG Health a global market leader in healthcare expert interviews with access to healthcare professionals across 50+ countries are addressing the unmet need of high quality primary research powered reports with Growth Plus Market Reports.
  • Growth + Market Reports, is a global life sciences market research reports platform that offers high quality market insights reports with a unique GrowthMIX approach.
  • All Growth+ reports come loaded with primary research, however the most differentiating factor remains complimentary access to Expert Connects Globally and Analyst Hours to build customizations complimentary with each report.

Insights from the world's leading KOLs on the prospects of launched and pipeline therapies for non-small cell lung cancer

Thursday, October 14, 2021 - 3:45pm

A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.

Key Points: 
  • A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.
  • In-depth interviews were conducted with 12 of the world's foremost KOLs in the United States and Europe.
  • How do KOLs assess Turning Point's pipeline repotrectinib and AnHeart's taletrectinib in the treatment of ROS1-positive NSCLC?
  • Why do KOLs expect Eli Lilly's late-stage Retevmo/Retsevmo and Blueprint Medicines/Roche's Gavreto will become front-line treatments for RET-fusion positive NSCLC?